PURPOSE: We investigated the long-term relationships between @entity2133 , fluid intake and @entity2182 symptoms in @entity1 undergoing treatment with @entity16912 . We hypothesized that @entity1 who experienced @entity2133 would increase their fluid intake and worsen their urinary symptoms. MATERIALS AND METHODS: We conducted a prospective ancillary study to a 9-month open-label trial of @entity16912 for @entity1 with urgency urinary incontinence. Fluid intake was measured and compared according to reported @entity2133 . Multivariable analysis was used to study the interaction between @entity2133 , fluid intake and urinary symptoms. RESULTS: During the study 407 @entity1 without @entity2133 significantly reduced their fluid intake (mean decrease 172.1 ml, median 118.3 ml, p = 0.02), while 91  @entity1 with @entity2133 did not (mean decrease 95.8 ml, median 118.3 ml, p  =  0.54). On univariable analysis a greater proportion of @entity1 who experienced @entity2133 reported improvement in their urinary symptoms compared to  @entity1 without @entity2133 (60.5% vs 47.2%, p = 0.03). On multivariable analysis black @entity1 were less likely to report @entity2133 (OR 0.4, 95% CI 0.2-0.9, p = 0.03) and older @entity1 were less likely to report improvement in urinary symptoms (OR 0.98, 95% CI 0.96-0.99, p = 0.003). Factors not associated with improvement in urinary symptoms on multiple regression were @entity2133 , baseline fluid intake volume, change in fluid intake volume and @entity5834 intake volume. CONCLUSIONS: In @entity1 with @entity2182 receiving @entity16912 @entity2133 may prevent restriction of fluid intake but does not diminish treatment efficacy.

Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in @entity1 taking XXXX .

@entity1 :: ('9606', 'Species') :: ['women'] @entity2133 :: ('MESH:D014987', 'Disease') :: ['dry mouth'] @entity16912 :: ('MESH:C526675', 'Chemical') :: ['fesoterodine'] @entity5834 :: ('MESH:D002110', 'Chemical') :: ['caffeine'] @entity2182 :: ('MESH:D053201', 'Disease') :: ['overactive bladder']
@entity16912 :: (MESH:C526675,Chemical) :: ['Fesoterodine']
